Cadrenal Therapeutics' SEC filings document the regulatory record of a Nasdaq-listed, emerging-growth biopharmaceutical company focused on immune, thrombotic, and anticoagulation-related disorders. Its 8-K reports disclose financial results, Regulation FD updates, clinical and regulatory events for CAD-1005, and scientific research involving 12-lipoxygenase inhibition.
The filings also cover capital-structure activity, including common-stock registrations, at-the-market offering materials, registered direct offerings, private-placement warrants, and related material agreements. Company disclosures identify its Delaware corporate status, Nasdaq Capital Market common stock listing, governance status as an emerging growth company, and formal reporting of pipeline developments involving CAD-1005, tecarfarin, and frunexian.
Cadrenal Therapeutics Chairman and CEO Quang X. Pham reported open-market sales of 4,126 shares of Common Stock at weighted average prices around $3.16–$3.18 per share. The sales on June 16–17, 2026 were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 25, 2025.
After these transactions, Pham holds 128,589 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power. The reported sales represent a small portion of his overall reported holdings and do not involve any derivative exercises.
Cadrenal Therapeutics is planning to seek U.S. FDA Rare Pediatric Disease Designation for tecarfarin to treat children with Kawasaki disease who develop coronary artery aneurysms and need chronic oral anticoagulation. The company highlights a dual-track portfolio: CAD-1005 as a first-in-class 12-LOX inhibitor for critical care, and tecarfarin for regional and rare indications.
If the designation is granted and tecarfarin is later approved, Cadrenal could receive a transferable Priority Review Voucher, with recent sales ranging from about $180 million to $205 million. CAD-1005 already holds Orphan Drug and Fast Track designations in the U.S. and orphan status in Europe for heparin-induced thrombocytopenia.
Cadrenal Therapeutics director and CEO Quang X Pham reported open-market sales of company stock. He sold a total of 18,124 shares of Cadrenal Therapeutics, Inc. common stock in three transactions on June 11, 12 and 15, 2026, at weighted average prices of $4.12, $3.94 and $3.58 per share.
The sales were made under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these transactions, Pham holds 132,715 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
CVKD reported multiple resale transactions of Common Stock by Quang X. Pham under Form 144. The filing lists individual dispositions on several dates in May–June 2026, including sales of 12,996 shares on 06/12/2026 and 12,992 shares on 06/09/2026.
The record also shows a line identifying Founders Shares: 40,000 shares (01/25/2022). The filing lists each sale with the number of shares and gross proceeds per trade; cash‑flow treatment is the selling holder's proceeds.
Cadrenal Therapeutics, Inc. Chairman, CEO and Interim CFO Quang X Pham reported open-market sales of a total of 22,385 shares of common stock over three days. Shares were sold at weighted average prices of about $4.38 on June 8, $4.06 on June 9, and $4.21 on June 10, in transactions described as carried out under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following these sales, Pham holds 150,839 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X. Pham reported open-market sales of a total of 8,285 shares of common stock on June 3–5, 2026 at weighted average prices of $4.26, $4.41 and $4.42 per share. These trades were executed under a pre-arranged Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the transactions, he holds 173,224 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, for which he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. reported that Chief Financial Officer Matthew K. Szot mutually agreed to transition out of his role effective May 28, 2026. Immediately afterward, the company appointed Chief Executive Officer Quang X. Pham as interim Chief Financial Officer and interim Principal Accounting Officer while it conducts a search for a permanent CFO.
Under a Severance Agreement dated June 3, 2026, Mr. Szot is entitled to a cash severance of $365,806.00 paid in four installments and his fiscal 2026 target cash bonus of $237,903.00 paid in two installments, all subject to standard deductions and withholdings. All of his outstanding stock options will fully vest and remain exercisable until their original expiration dates. The agreement includes a seven-day Revocation Period, a general release of claims, and a non-disparagement clause.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang Pham reported small open-market sales of company common stock. He sold 303 shares on May 29, 2026 at a weighted average price of $5.01 per share and 349 shares on June 2, 2026 at a weighted average price of $4.46 per share, totaling 652 shares. The sales were executed under a pre-arranged Rule 10b5-1 trading arrangement. After these transactions, Pham holds 181,509 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power.
Cadrenal Therapeutics, Inc. CEO and Chairman Quang X Pham reported open-market sales of 12,763 shares of common stock. The sales occurred on May 11, May 12, and May 28, 2026, at reported weighted average prices of $5.76, $5.28, and $4.93 per share.
The footnotes state these transactions were made under a Rule 10b5-1 trading arrangement adopted on September 25, 2025. Following the latest sale, Pham holds 182,161 shares directly and 200,000 shares indirectly through The PVBQ Living Trust, where he has sole voting and dispositive power. The filing also corrects an earlier understatement of indirect holdings on a prior Form 4.
Cadrenal Therapeutics CEO and Chairman Quang Pham reported an open-market sale of 1,165 shares of Common Stock on May 22, 2026 at a weighted average price of $5.69 per share, executed as an "S" code transaction.
The sale was made pursuant to a Rule 10b5-1 trading arrangement adopted on September 25, 2025, meaning it was pre-arranged. After the sale, Pham directly owns 194,924 shares of Cadrenal Therapeutics common stock and indirectly holds 20,000 shares through The PVBQ Living Trust, where he serves as trustee with sole voting and dispositive power.